Brain metastases are a common complication in EGFR-mutated NSCLC patients, which could be targeted by the third-generation EGFR-TKI as a CNS-penetrant drug (Gillespie et al., 2023). This evidence concerns the gene EGFR and non-small cell lung carcinoma.